BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38294544)

  • 1. Assessment of hydroxychloroquine blood levels in Sjögren's disease patients: drug adherence and clinical associations.
    Pasoto SG; Villamarín LEB; de Vinci Kanda Kupa L; Deveza GBH; Ribeiro CT; Emi Aikawa N; Leon EP; de Oliveira Martins VA; Silva CA; Bonfa E
    Rheumatol Int; 2024 Jul; 44(7):1305-1315. PubMed ID: 38294544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary Sjögren's syndrome: Extraglandular manifestations and hydroxychloroquine therapy.
    Demarchi J; Papasidero S; Medina MA; Klajn D; Chaparro Del Moral R; Rillo O; Martiré V; Crespo G; Secco A; Catalan Pellet A; Amitrano C; Crow C; Asnal C; Pucci P; Caeiro F; Benzanquen N; Pirola JP; Mayer M; Zazzetti F; Velez S; Barreira J; Tamborenea N; Santiago L; Raiti L
    Clin Rheumatol; 2017 Nov; 36(11):2455-2460. PubMed ID: 28913747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is hydroxychloroquine effective in treating primary Sjogren's syndrome: a systematic review and meta-analysis.
    Wang SQ; Zhang LW; Wei P; Hua H
    BMC Musculoskelet Disord; 2017 May; 18(1):186. PubMed ID: 28499370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of sicca symptoms with hydroxychloroquine in patients with Sjogren's syndrome.
    Rihl M; Ulbricht K; Schmidt RE; Witte T
    Rheumatology (Oxford); 2009 Jul; 48(7):796-9. PubMed ID: 19433433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort.
    Geraldino-Pardilla L; Perel-Winkler A; Miceli J; Neville K; Danias G; Nguyen S; Dervieux T; Kapoor T; Giles J; Askanase A
    Lupus; 2019 Jun; 28(7):862-867. PubMed ID: 31122136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term hydroxychloroquine therapy improves the quality of sleep in patients with primary Sjögren's syndrome: a real-world study.
    Guan P; Sun C; Chen Z; Chen J; Ran R
    Ann Palliat Med; 2020 Jul; 9(4):2203-2210. PubMed ID: 32692242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study.
    Fox RI; Dixon R; Guarrasi V; Krubel S
    Lupus; 1996 Jun; 5 Suppl 1():S31-6. PubMed ID: 8803908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revisiting the JOQUER trial: stratification of primary Sjögren's syndrome and the clinical and interferon response to hydroxychloroquine.
    Collins A; Lendrem D; Wason J; Tarn J; Howard-Tripp N; Bodewes I; Versnel MA; Gottenberg JE; Seror R; Mariette X; Ng WF
    Rheumatol Int; 2021 Sep; 41(9):1593-1600. PubMed ID: 34165604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxychloroquine improves dry eye symptoms of patients with primary Sjogren's syndrome.
    Yavuz S; Asfuroğlu E; Bicakcigil M; Toker E
    Rheumatol Int; 2011 Aug; 31(8):1045-9. PubMed ID: 20309693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of cellular text messaging for improving adherence among adolescents and young adults with systemic lupus erythematosus.
    Ting TV; Kudalkar D; Nelson S; Cortina S; Pendl J; Budhani S; Neville J; Taylor J; Huggins J; Drotar D; Brunner HI
    J Rheumatol; 2012 Jan; 39(1):174-9. PubMed ID: 22089460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salivary gland LAMP3 mRNA expression is a possible predictive marker in the response to hydroxychloroquine in Sjögren's disease.
    Nakamura H; Tanaka T; Ji Y; Zheng C; Afione SA; Warner BM; Oliveira FR; Motta ACF; Rocha EM; Noguchi M; Atsumi T; Chiorini JA
    PLoS One; 2023; 18(2):e0282227. PubMed ID: 36821638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of obesity on hydroxychloroquine blood levels in lupus nephritis patients.
    Pedrosa T; Kupa LVK; Pasoto SG; Aikawa NE; Borba EF; Duarte NJ; Leon EP; Silva CA; Bonfá E
    Lupus; 2021 Apr; 30(4):554-559. PubMed ID: 33402039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sjögren's syndrome in the JOQUER randomized trial.
    Bodewes ILA; Gottenberg JE; van Helden-Meeuwsen CG; Mariette X; Versnel MA
    Rheumatology (Oxford); 2020 Jan; 59(1):107-111. PubMed ID: 31237947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren's syndrome patients.
    Bai W; Yang F; Xu H; Wei W; Li H; Zhang L; Zhao Y; Shi X; Zhang Y; Zeng X; Leng X
    Trials; 2023 Feb; 24(1):112. PubMed ID: 36793118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Articular and Peripheral Nervous System Involvement Are Linked to the Long-Term Outcome in Primary Sjögren's Syndrome: The Relevance of Single Organ Manifestations Rather Than a Composite Score as Predictors.
    Quartuccio L; Gandolfo S; Zabotti A; Zandonella Callegher S; Fabro C; De Vita S
    Front Immunol; 2019; 10():1527. PubMed ID: 31354708
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of hydroxychloroquine on the lipid profile of patients with Sjögren syndrome.
    Migkos MP; Markatseli TE; Iliou C; Voulgari PV; Drosos AA
    J Rheumatol; 2014 May; 41(5):902-8. PubMed ID: 24634203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxychloroquine was associated with reduced risk of new-onset diabetes mellitus in patients with Sjögren syndrome.
    Chen TH; Lai TY; Wang YH; Chiou JY; Hung YM; Wei JC
    QJM; 2019 Oct; 112(10):757-762. PubMed ID: 31218368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salivary and serum B-cell activating factor (BAFF) levels after hydroxychloroquine treatment in primary Sjögren's syndrome.
    Mumcu G; Biçakçigil M; Yilmaz N; Ozay H; Karaçayli U; Cimilli H; Yavuz S
    Oral Health Prev Dent; 2013; 11(3):229-34. PubMed ID: 23878841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative analysis of the efficacy and safety of herbal decoction CheReCunJin alone and combined with hydroxychloroquine for treating primary Sjögren's syndrome: A randomized controlled trial.
    Shao Q; Jin L; Li C; Wang J; Wang M; Wang Q; Wu B
    Explore (NY); 2022; 18(4):416-422. PubMed ID: 34417112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of primary Sjögren's syndrome with hydroxychloroquine.
    Fox RI; Chan E; Benton L; Fong S; Friedlaender M; Howell FV
    Am J Med; 1988 Oct; 85(4A):62-7. PubMed ID: 3177432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.